This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kroon, C. Articles by Cohen, A. F. Search for Related Content PubMed PubMed Citation Articles by Kroon, C. Articles by Cohen, A. F. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Thinners Heart Attack Hazardous Substances DB HEPARIN

Circulation, Vol 86, 1370-1375, Copyright © 1992 by American Heart Association

ARTICLES

Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers

C Kroon, WR ten Hove, A de Boer, JM Kroon, JM van der Pol, EJ Harthoorn- Lasthuizen, HC Schoemaker, FJ van der Meer and AF Cohen
Centre for Human Drug Research, University Hospital, Leiden, The Netherlands.

BACKGROUND. In this study, the anticoagulant response of 12,500 IU heparin s.c. was investigated in patients with myocardial infarction and healthy volunteers to determine variabilities in response and modifying factors. METHODS AND RESULTS. On the fourth day after thrombolytic therapy, blood samples were taken before and at frequent intervals until 10 hours after the injection of 12,500 IU heparin s.c. Plasma anti-Xa activity, anti-IIa activity, and the activated partial thromboplastin time (APTT) were measured in addition to body weight and thickness of the abdominal subcutaneous fat layer. Contrary to expectations, the increase of anti-Xa activity, anti-IIa activity, and APTT compared with baseline (predrug) levels was very small, with an average maximal APTT of 42.6 seconds (SD, 12.4 seconds; range, 30.4- 70.7 seconds). Subsequently, the influence of the length of the injection needle on the anticoagulant effect of 12,500 IU heparin s.c. was studied in 10 healthy volunteers to find a factor that could be responsible for the poor response in the patients. The length of the injection needle did not influence the anticoagulant effect of heparin. Large interindividual and intraindividual variabilities were seen in the volunteers. The majority of volunteers had minimal prolongation of the APTT, but very strong prolongation was also seen (maximal APTT, 163 seconds). There was no correlation between the abdominal skinfold thickness and anti-Xa activity, anti-IIa activity, or APTT (p > 0.05), but in the patient study, there was a correlation between weight and anti-Xa activity and anti-IIa activity (p < 0.05), and in the volunteer study, there was a correlation between weight and anti-Xa activity and APTT (p < 0.05). CONCLUSIONS. Subcutaneous administration of heparin in a fixed dose for prophylactic and therapeutic purposes may be inadequate because of the large interindividual and intraindividual variations in anticoagulant effect.

This article has been cited by other articles:

				S A J Chamuleau, R J de Winter, M Levi, R Adams, H R Büller, M H Prins, K I Lie, and R J G Peters Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study Heart, July 1, 1998; 80(1): 35 - 39. [Abstract] [Full Text]

				F. Catella-Lawson and G. A. FitzGerald Confusion in Reperfusion: Problems in the Clinical Development of Antithrombotic Drugs Circulation, February 18, 1997; 95(4): 793 - 795. [Full Text]

				H. V. Anderson and J. T. Willerson Thrombolysis in Acute Myocardial Infarction N. Engl. J. Med., September 2, 1993; 329(10): 703 - 709. [Full Text]